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Abstract
OBJECTIVES To develop a ‘Patient Monitoring 
Tool’ (PMT) to evaluate the quality of pharmaceutical 
care provided to patients in a psychiatric setting and to 
determine benefits of ward-based pharmacist services in 
this setting.  
METHOD A PMT consisting of ‘Patient Monitoring 
Guidelines’ (PMG) and a ‘Pharmaceutical Care Issues 
Documentation Sheet’ (PCIDS) was developed. The tool 
was tested for validity, applicability, practicality and 
reliability and used to monitor 30 patients in an acute 
psychiatric ward. The PMT was implemented and evaluation 
was carried out after 4 weeks using a self-administered 
evaluation questionnaire. 
KEY FINDINGS The developed PMT was found 
to be valid, applicable, practical and reliable for use in 
the psychiatric setting. A total of 75 pharmaceutical care 
issues (PCIs) were identified; 55 involved psychotropic 
medications. A positive evaluation of the tool was obtained. 
CONCLUSION This study demonstrated that the 
proposed tool can be implemented in an acute psychiatric 
setting and patient monitoring may lead to optimisation 
of patient care. Pharmacist incorporation into the multi-
disciplinary healthcare team and direct patient involvement 
may further enhance the value of such services. 
KEYWORDS Patient Monitoring, Pharmaceutical 
Care Issues, Pharmacist Intervention, Psychiatry 
Introduction 
Psychiatric patients are a high-risk patient population posing 
several challenges for the provision of safe and effective 
pharmaceutical care.1 Many psychotropic medications have 
a narrow therapeutic index and polypharmacy is common. 
Moreover, patients with psychiatric conditions are becoming 
an aging population, mirroring the demographics of the 
general population with an increased potential for medical 
co-morbidities requiring treatment with additional non-
psychotropic medications leading to potential drug-drug 
and drug-disease interactions.2
Over the past few decades the pharmacist’s role has 
evolved from being predominantly product-focused 
to patient-oriented, targeted at improving the quality 
of drug therapy and enhancing patient safety through 
clinical pharmacy services.3 Patient monitoring and 
provision of recommendations regarding dosing and 
administration of medications, contemporary evidence-
based treatment guidelines, adverse drug reactions, 
drug-drug interactions and therapeutic drug monitoring 
are pharmacist interventions which may contribute to 
prevention and resolution of pharmaceutical care issues 
(PCIs), leading to cost reductions, shorter hospital stays 
and improved patient care.4 Documentation of PCIs instils 
pharmacist accountability, enhances continuity of care 
and demonstrates the importance of PIs in the provision 
of high-quality pharmaceutical care and optimisation of 
patient outcomes.5,6 
The aim of this study was to develop a ‘Patient Monitoring 
Tool’ (PMT) to evaluate the quality of pharmaceutical 
care provided to patients in a psychiatric setting and to 
determine benefits of ward-based pharmacist services in 
this setting. 
Method 
This study was carried out at Mount Carmel Hospital (MCH), 
a 400-bed hospital offering mental health and geriatric 
services. Approval was granted by the Clinical Chairperson 
and Head of Pharmacy Services at the hospital.
A draft ‘Patient Monitoring Tool’ (PMT) consisting of ‘Patient 
Monitoring Guidelines’ (PMG), a comprehensive six-step 
method guiding the pharmacist during patient monitoring, 
The tool developed allows 
standardisation of patient 
monitoring and documentation 
of pharmaceutical care issues
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and a ‘Pharmaceutical Care Issues Documentation Sheet’ 
(PCIDS), allowing standardised documentation of PCIs 
identified, were developed. A panel of 8 healthcare 
professionals from within and outside the hospital was asked 
to validate the draft PMG and PCIDS. Each validation panel 
member was given a consent form, a draft version of the 
tool and a validation questionnaire to assess presentation, 
comprehensiveness and validity and allowing inclusion 
of further comments. The validation questionnaires were 
scored out of a total score of 11 for the PMG and out of 10 
for the PCIDS. The PMT was amended following validation 
and a second draft was developed.  
A pilot study was undertaken to assess the applicability 
and practicality of the PMT to determine its feasibility and 
adequacy for use in the practical scenario. The principal 
investigator (MM) followed the PMG during the monitoring 
of 10 patients and documented identified PCIs in the PCIDS. 
Inter-observer reliability testing was determined by asking 
another investigator to monitor the same 10 patients. Both 
investigators were pharmacists. Data was inputted into IBM 
SPSS® version 21 to analyse the correlation between scores 
obtained by the two investigators using the Kappa statistic. 
Subsequently, a meeting between the two investigators was 
held to discuss PCIs identified, including any discrepancies 
and their relevance to clinical practice. 
No changes to the PMT were made following the pilot 
study so the 10 patients were included in the actual study. 
A total of 30 patients were monitored in the actual study 
to evaluate the quality and safety of pharmaceutical care 
provided. Patients were chosen by convenience sampling 
from those admitted at the Mixed Admissions Ward (MAW), 
an acute ward for both male and female patients between 
the age of 12 to 90 years experiencing a first or an acute 
psychiatric episode. On completion of this study and 
following appropriate training of two other pharmacists, 
the PMT was implemented for use in practice during weekly 
patient monitoring sessions in which medication review of 
newly admitted patients is carried out. Evaluation of the 
tool was undertaken one month after implementation 
using a self-administered questionnaire.
Results
Validation of the PMG resulted in a mean validation score of 
10.7 (range 10.5 to 11.0) and the mean validation score for 
the PCIDS was 9.6 (range 9.5 to 10.0). The applicability and 
practicality study demonstrated that the PMT is applicable 
and practical to use in the psychiatric setting and no 
further amendments were deemed necessary. Monitoring 
of patient’s treatment was fairly time consuming, however 
time taken generally depended on the complexity of the 
patient’s situation. During inter-observer reliability testing, 
20 out of a total of 25 identified PCIs were common to 
both pharmacists. This resulted in a Kappa value of 0.574 
implying moderate agreement between PCIs identified 
by the two pharmacists. During the post-study meeting it 
was agreed that although some inconsistencies between 
PCIs identified did exist, these minimal differences which 
could be attributed to difference in professional experience 
and judgement had no detrimental effect on the patients’ 
medical condition. 
Demographics of the 30 patients monitored are shown 
in Table 1. Seventeen patients (8 male and 9 female) were 
identified as high-risk patients, namely ≥ 65 years old or 
suffering from co-morbidities including cardiovascular 
disorders, diabetes, hepatic and/or renal impairment. A 
total of 164 medications were prescribed in the 30 patients 
monitored, with the majority (n=100) being psychotropic 
medications. An average of 6 medications was prescribed 
for each patient, ranging from 1 to 12 medications per 
patient. The most commonly identified PCIs included 
long-term use of benzodiazepines, clinically significant 
interactions and improper drug selection. A quantitative 
analysis of PCIs identified is compiled in Table 2 and 
categorisation of PCIs is shown in Table 3. Experience from 
implementation of the PMT was positive and evaluation 
demonstrated that the tool is fit for purpose, user friendly 





Mean age (range) of patients in years 54.4 (23-88)
Males 52.9 (23-88)
Females 56.4 (30-75)




PRN (as needed) medications 28
Psychotropic 15
Non-psychotropic 13
Mean number (range)  
of medications per patient 5.56 (1-12)
Males 4.94 (1-10)
Females 6.38 (5-12)
Table 1: Patient demographics according to gender (N=30)
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Discussion
At MCH, similar to other local settings, a large proportion of 
pharmacist time is being spent on administrative services 
which could be delegated to pharmacy technicians and 
other trained staff.7 This study confirms the applicability of 
the developed tool as a means to introduce a structured 
clinical pharmacy service in a psychiatric hospital. 
Promoting safe medication use in a psychiatric hospital 
necessitates adopting lessons learnt from other health 
care settings, whilst concomitantly focusing on strategies 
directed at the unique challenges of psychiatry.8 
A significant proportion of PCIs identified involved 
psychotropic medications. This result differs to studies 
by Alderman2 and O’Hare9 et al. in which the majority of 
 Numberof PCIs
Total number of patients in whom PCIs were identified 27
Total number of PCIs identified 75
Mean number (range) of PCIs identified per patient 2.5 (0-7)
Males 3.08 (0-6)
Females 2.06 (0-7)
PCIs: Pharmaceutical care issues
Table 2: Quantitative analysis of pharmaceutical care issues identified (N=30)
Pharmaceutical Care Issue Frequency 




Improper drug selection 13
Identified clinically significant interactions 15
Need for additional drug 5
Unclear/Unconfirmed indication 0
Inappropriate dosage form 0 Dosage form 




Dose too high 6
Dosage regimen not frequent enough 4
Dosage regimen too frequent 1
Drugs given PRN despite practice not recommended 1
Drugs with slow titration 0
Untreated indication 0 Drug effect 
Prescribing error (wrong or missing information) 1 Logistics (n=1)
Others (including long-term use of benzodiazepines, medications to be 
used with caution in patients with comorbidities, wrong timing of doses) 18
Others 
(n=18)
Table 3: Categorisation of pharmaceutical care issues identified (n=75)
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pharmacist interventions were related to non-psychotropic 
drugs. A plausible explanation may be that the majority of 
medications (73%) prescribed in patients included in this 
study are psychiatric medications. 
The evolution of the pharmacist’s role from a product-
centred profession to one which makes the patient the 
fulcrum of its activities has been ongoing in various Maltese 
healthcare settings such as geriatric and rehabilitative 
care10-12 and rheumatology.13-15 However, in the psychiatric 
setting, evolution of the pharmacist’s role is happening at 
a much slower pace.16 This may be due to lack of human 
resources and the stigma associated with mental health. 
Nevertheless, the pharmacy department at MCH aims to 
extend the services offered to include clinical services in 
this setting, together with allocation of more manpower. 
This may be done through adaptation of clinical pharmacy 
standards established in other settings11,12 to enhance 
patient monitoring and enable identification of PCIs to 
ensure safe and effective medication use and improve 
patient outcomes. Standardisation of documentation of 
PCIs may be considered as the first steps towards enhancing 
the quality of patient care.11,12
Various limitations of the study were identified. Patient 
monitoring was carried out on a small sample of inpatients, in 
an acute ward, under the care of six consultant psychiatrists 
which may limit extrapolation of results to the entire patient 
population at MCH. Identification of PCIs relied heavily upon 
experience and professional judgement of the pharmacist 
and patient monitoring was carried out solely through 
review of medication records which sometimes consisted 
of poorly recorded and/or incomplete documentation. 
Moreover, PCIs identified and recommendations made did 
not take into consideration patient input, hence important 
PCIs including adverse drug reactions and adherence to 
treatment could not be determined.   
Conclusion
This study demonstrated that pharmaceutical care being 
provided to inpatients at MCH may be optimised. The tool 
developed allows standardisation of patient monitoring 
and documentation of PCIs. The provision of clinical 
pharmacy services such as monitoring of patients in an 
acute psychiatric ward can contribute to amelioration of 
patient care and safer use of medications. The value of 
the provision of such services may be further enhanced 
through direct patient interaction and the integration of 
the pharmacist into the multidisciplinary healthcare team 
especially during ward rounds.
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